Slagle Financial LLC Raises Stock Holdings in Pfizer Inc. (NYSE:PFE)

Slagle Financial LLC grew its holdings in Pfizer Inc. (NYSE:PFE) by 6.1% in the 4th quarter, Holdings Channel.com reports. The fund owned 73,628 shares of the biopharmaceutical company’s stock after buying an additional 4,264 shares during the period. Slagle Financial LLC’s holdings in Pfizer were worth $1,953,000 as of its most recent SEC filing.

Several other hedge funds also recently added to or reduced their stakes in the business. Retirement Wealth Solutions LLC purchased a new position in Pfizer during the fourth quarter worth approximately $26,000. Rialto Wealth Management LLC acquired a new stake in Pfizer in the 4th quarter valued at $26,000. Kohmann Bosshard Financial Services LLC acquired a new position in Pfizer during the fourth quarter worth $28,000. Noble Wealth Management PBC purchased a new position in Pfizer during the fourth quarter valued at $31,000. Finally, Curio Wealth LLC acquired a new stake in shares of Pfizer in the fourth quarter valued at about $32,000. 68.36% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Pfizer

In other news, Director Ronald E. Blaylock bought 19,457 shares of the stock in a transaction on Thursday, February 13th. The stock was purchased at an average cost of $25.65 per share, with a total value of $499,072.05. Following the purchase, the director now owns 27,707 shares of the company’s stock, valued at approximately $710,684.55. The trade was a 235.84 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available at this link. 0.06% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

PFE has been the topic of a number of research reports. Guggenheim reaffirmed a “buy” rating on shares of Pfizer in a research note on Tuesday, March 18th. Truist Financial dropped their price target on Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a research report on Wednesday, December 18th. Citigroup lowered their target price on shares of Pfizer from $30.00 to $29.00 and set a “neutral” rating on the stock in a research note on Tuesday, January 28th. Bank of America reiterated a “neutral” rating and issued a $29.00 target price on shares of Pfizer in a research report on Tuesday, December 10th. Finally, Hsbc Global Res upgraded shares of Pfizer to a “strong-buy” rating in a research report on Monday, March 10th. One analyst has rated the stock with a sell rating, seven have assigned a hold rating, six have assigned a buy rating and three have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $31.92.

Pfizer Trading Down 0.6 %

Shares of Pfizer stock opened at $25.05 on Friday. The company’s fifty day moving average is $26.09 and its two-hundred day moving average is $26.97. Pfizer Inc. has a 1 year low of $24.48 and a 1 year high of $31.54. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. The company has a market capitalization of $142.08 billion, a P/E ratio of 17.77, a PEG ratio of 0.64 and a beta of 0.61.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, beating analysts’ consensus estimates of $0.48 by $0.15. The firm had revenue of $17.76 billion for the quarter, compared to analyst estimates of $17.26 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. Pfizer’s quarterly revenue was up 24.7% on a year-over-year basis. During the same period last year, the firm posted $0.10 EPS. Analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.